Hot topics | Coronavirus pandemic

Vaccine mix-and-match technique boosts antibodies, according to a new study

Vaccine mix-and-match technique boosts antibodies, according to a new study

According to preliminary results of a long-awaited US government-sponsored trial, mixing COVID vaccines produces as many or more antibodies as using the same shot as reactivator.

The trial is the first major US study to compare the benefits of using different vaccines as boosters from the initial shot or shots. The lengthy, 9-arm trial involved over 450 individuals and examined the effects of giving a booster shot of the Moderna Inc., Pfizer Inc, BioNTech SE, or Johnson & Johnson vaccines to individuals who had previously received fewer vaccine doses.

Overall, the study revealed that mixing-and-matching produced comparable or higher levels of neutralizing antibodies than same-vaccine boosting, according to the researchers in the preprint posted on medRxiv.org. The study found that the incidence of adverse events was comparable across all the different booster groups.

These data suggest that if a vaccine is approved or approved as reactivator, an immune response will be created regardless of the primary Covid-19 vaccination regimen, said the researchers in their conclusion.

The results of the ongoing trial have not yet been peer reviewed and published in a medical journal. More information about the study is expected to be revealed Friday afternoon at a meeting of the FDA advisory panel, where researchers conducting the trial are expected present their early findings.

Mixing and matching boosters have become increasingly important issues. Many other countries outside of the US have adopted the method in an attempt to increase vaccine effectiveness or avoid some of its potentially harmful side effects.

In the United States, some individuals who received the Johnson & Johnson shot may be interested in receiving a messenger RNA shot as opportune booster. Mixing-and-matching might make it easier for officials to deploy boosters more broadly, since those receiving booster shots may have any Covid vaccine on hand at their pharmacy and wouldnt have to search for the shot they had previously received.

Outside of the United States, fears about rare blood clots linked to AstraZeneca Plcs vaccine prompted many countries in Europe to halt use of this shot and instead administer a different second dose. In the United Kingdom, health authorities have implemented a booster program that includes an extra dose of the Pfizer vaccine as the preferred option, as well as omitting severance doses of Moderna vaccine.

You may also like: